The FDA’s approval last month of “two rapid at-home antigen tests, Abbott’s BinaxNOW and Quidel’s QuickVue, [which] will soon be sold over the counter on drugstore shelves, without the need for a prescription.” The article says these approvals have critical potential impact on the testing front and will help the US catch up to other developed nations in terms of rapid antigen testing. The piece highlights comments in an interview by Bruce Tromberg, director of the National Institute of Biomedical Imaging and Bioengineering, who said, “We are in a risky period with variant growth, incomplete vaccination, return to school, increased population mobility and reduced mask wearing. … The need to do screening, using accessible tests at home, on a large scale and on a regular cadence, is even more important.” Source: Scientific American
